Mounjaro and Endometriosis: Can Weight Loss on Tirzepatide Help Manage Symptoms?

Mounjaro and endometriosis is a topic that more women are asking about, and for good reason. Endometriosis is an oestrogen-driven inflammatory condition that affects roughly one in ten women of reproductive age in the UK. As a result, emerging evidence suggests that weight loss on tirzepatide may help reduce the chronic inflammation and hormonal imbalance that fuel its symptoms.

In this article, Dr Emil Gadimali explains the biological connection between excess weight and endometriosis. Furthermore, he reviews the current evidence on GLP-1 agonists for this condition and offers practical guidance for women considering Mounjaro treatment at CutKilo.

Mounjaro is not licensed to treat endometriosis. In fact, no clinical trial has yet tested tirzepatide specifically for endometriosis pain. However, the weight loss and anti-inflammatory effects of tirzepatide target two central drivers of endometriosis symptoms: excess oestrogen from adipose tissue and chronic systemic inflammation.

Early clinical research supports this connection. For instance, a Phase II trial investigating tirzepatide for oestrogen-driven endometrial conditions is now registered on ClinicalTrials.gov. In addition, observational evidence also suggests that GLP-1 agonists may offer a meaningful secondary benefit for women with endometriosis who carry excess weight.

This does not mean Mounjaro replaces established endometriosis treatments. Rather, it means that for women who qualify for weight-loss treatment, addressing obesity may also improve endometriosis outcomes.

How endometriosis works

Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus. It most commonly appears on the ovaries, fallopian tubes, and pelvic peritoneum. Because this tissue responds to oestrogen, it grows and bleeds with each menstrual cycle. Consequently, this causes pain, inflammation, and sometimes scarring or adhesions. NICE guideline NG73 recognises the condition’s significant impact on quality of life.

The oestrogen connection

The connection to body weight centres on oestrogen. In particular, adipose tissue is not simply a passive store of energy. It is an active endocrine organ that produces oestrogen through an enzyme called aromatase. This enzyme converts androgens into oestradiol. Therefore, the more adipose tissue a woman carries, the higher her circulating oestrogen levels tend to be. In endometriosis, this additional oestrogen acts as fuel because it stimulates the growth and inflammatory activity of endometrial implants.

Amplified inflammation

Excess weight also amplifies systemic inflammation. For example, adipose tissue releases pro-inflammatory mediators including interleukin-6, TNF-alpha, and C-reactive protein (CRP). All of these are elevated in women with endometriosis. Indeed, a review in Human Reproduction Update highlighted that this adipose-driven inflammatory environment may worsen endometriosis-related pain and disease progression.

Reducing oestrogen through fat loss

Tirzepatide, the active ingredient in Mounjaro, produces clinically significant weight loss. In the SURMOUNT-1 trial published in the New England Journal of Medicine, participants lost an average of 20.9% of their body weight on the highest dose over 72 weeks. As a result, this degree of fat loss substantially reduces circulating oestrogen levels. In other words, less adipose tissue means less aromatase activity and less oestrogen production.

Anti-inflammatory effects

In addition, tirzepatide has potent anti-inflammatory effects. CutKilo patients routinely see reductions in CRP and other inflammatory markers during treatment. For women with endometriosis, therefore, lowering systemic inflammation may reduce the inflammatory cascade that drives pelvic pain, bloating, and fatigue.

Ongoing clinical research

A Phase II clinical trial (registered on ClinicalTrials.gov) is now investigating tirzepatide for fertility-sparing treatment in patients with obesity who have oestrogen-driven endometrial conditions. This includes atypical endometrial hyperplasia. Similarly, the biological rationale is shared with endometriosis: reducing oestrogen exposure through weight loss and metabolic improvement. Consequently, positive results would strengthen the case for GLP-1 agonists in oestrogen-driven gynaecological conditions more broadly.

Body composition changes matter just as much as the number on the scales. In particular, fat loss from visceral stores has a disproportionately large effect on oestrogen production and inflammatory marker reduction. Women who want to track these changes objectively may benefit from a body composition scan at DEXA London, CutKilo’s sister service. This can quantify visceral fat and lean mass changes during treatment.

Transparency about the current evidence base is important. To be clear, no randomised controlled trial has yet tested Mounjaro or any GLP-1 agonist as a direct treatment for endometriosis. The case for benefit rests on three pillars: first, the established link between adipose tissue and oestrogen production; second, the proven anti-inflammatory effects of tirzepatide; and third, early clinical research in adjacent oestrogen-driven conditions.

Moreover, observational data from women using GLP-1 medications while managing endometriosis is emerging. A review by Happiher Health aggregated clinical observations from multiple gynaecology practices. It reported that women on GLP-1 therapy frequently noted reductions in pelvic pain, bloating, and menstrual heaviness. However, these are self-reported outcomes, not trial endpoints. Therefore, they should be interpreted with appropriate caution.

What we can say with confidence is that losing excess weight improves hormonal balance and reduces inflammation. Both of these changes benefit endometriosis. Nevertheless, the question is whether tirzepatide offers additional, direct benefits on endometrial tissue beyond weight loss. That question remains open.

Many women with endometriosis are also concerned about fertility. Indeed, endometriosis is a leading cause of subfertility in the UK. In addition, obesity independently reduces the chance of conception and increases the risk of pregnancy complications. As a result, by addressing excess weight, Mounjaro may indirectly improve fertility prospects for women with endometriosis and a raised BMI.

However, you must stop Mounjaro before attempting to conceive. The MHRA SmPC advises discontinuing tirzepatide at least one month before a planned pregnancy. Alternatively, two months is a more conservative recommendation that some specialists prefer. Women at CutKilo who are planning pregnancy receive counselling about this timeline as part of their treatment plan. For a full discussion of this topic, see our guide on Mounjaro and fertility.

If you have endometriosis and are considering weight-loss treatment at CutKilo, discuss these points with your medical team.

Continue your existing treatment

Whether you take hormonal contraceptives, GnRH analogues, or progestogens, do not stop or modify them because you are starting Mounjaro. Specifically, tirzepatide slows gastric emptying. As a result, this could theoretically affect absorption of oral medications. If you take the combined oral contraceptive pill, therefore, discuss timing with your prescriber to ensure contraceptive efficacy is maintained.

Keep a symptom diary

Track your pelvic pain, bloating, fatigue, and menstrual patterns before and during Mounjaro treatment. This will help you and your gynaecologist assess whether weight loss has a measurable impact on your endometriosis symptoms. Most importantly, the improvement may be gradual rather than dramatic.

Prioritise nutrition

Women with endometriosis who are losing weight rapidly on Mounjaro need adequate intake of iron, omega-3 fatty acids, and anti-inflammatory nutrients. Because reduced caloric intake combined with heavy menstrual periods increases the risk of iron deficiency anaemia, your CutKilo doctor can arrange blood tests to monitor this.

For women living with both endometriosis and excess weight, the most important clinical insight is this: reducing adipose tissue reduces oestrogen production and systemic inflammation. Both of these drive endometriosis progression and pain. In fact, Mounjaro achieves this more effectively than lifestyle modification alone.

We await dedicated clinical trials. However, the biological rationale is strong, the early clinical observations are encouraging, and the broader health benefits of treating obesity are clear. Overall, women at CutKilo who manage endometriosis alongside their weight should view Mounjaro treatment as potentially complementary to their existing gynaecological care, not as a replacement for it.

Will Mounjaro cure my endometriosis?

No. Endometriosis is a chronic condition with no known cure. However, Mounjaro may help manage symptoms by reducing oestrogen levels and inflammation through weight loss. It does not eliminate endometrial implants. As a result, surgical excision and hormonal therapies remain the mainstay of treatment as recommended by NICE guideline NG73.

Can I take Mounjaro with my endometriosis medication?

In most cases, yes. The MHRA SmPC for tirzepatide does not list direct interactions with hormonal treatments commonly used for endometriosis. This includes progestogens, the combined pill, and GnRH analogues. However, Mounjaro slows gastric emptying. Therefore, oral medications may absorb more slowly as a result. Discuss timing and spacing of your medications with your prescriber.

How much weight loss is needed to see a difference?

Research on obesity and hormonal conditions suggests that a loss of 5 to 10 per cent of body weight can produce measurable reductions in circulating oestrogen and inflammatory markers. For example, for a woman weighing 90 kg, this equates to roughly 4.5 to 9 kg. Many CutKilo patients achieve this within the first three to four months of treatment.

Is Mounjaro safe if I am trying to get pregnant?

You must stop Mounjaro before attempting to conceive. Specifically, the recommended washout period is at least one to two months. Losing excess weight before pregnancy can improve fertility outcomes. Therefore, plan the timing of stopping Mounjaro with your doctor. Our article on Mounjaro and fertility covers this in detail.

Will my symptoms return if I stop Mounjaro?

If weight returns after stopping Mounjaro, oestrogen production from adipose tissue will increase again. Similarly, inflammatory markers may also rise. As a result, this could lead to a recurrence or worsening of symptoms. That is why long-term weight maintenance strategies are essential. Your CutKilo doctor will help you plan for this transition.